Article info
PDFOriginal research
Practical allocation system for the distribution of specialised care during cellular therapy access scarcity
- Correspondence to Dr Andrew Hantel, Department of Medicine, Section of Hematology/Oncology, The University of Chicago, Chicago IL 60637, USA; ahantel{at}medicine.bsd.uchicago.edu
Citation
Practical allocation system for the distribution of specialised care during cellular therapy access scarcity
Publication history
- Received December 30, 2018
- Revised April 5, 2019
- Accepted April 27, 2019
- First published June 19, 2019.
Online issue publication
August 27, 2019
Article Versions
- Previous version (27 August 2019).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events
- Both APRIL and antibody-fragment-based CAR T cells for myeloma induce BCMA downmodulation by trogocytosis and internalization
- PD-L1 blockade restores CAR T cell activity through IFN-γ-regulation of CD163+ M2 macrophages
- Assessment and predictive ability of the absolute neutrophil count in peripheral blood for in vivo CAR T cells expansion and CRS
- Severe early hepatitis B reactivation in a patient receiving anti-CD19 and anti-CD22 CAR T cells for the treatment of diffuse large B-cell lymphoma
- Blockade of AIM2 inflammasome or α1-AR ameliorates IL-1β release and macrophage-mediated immunosuppression induced by CAR-T treatment
- CAR T cells for treating autoimmune diseases
- Systemically administered low-affinity HER2 CAR T cells mediate antitumor efficacy without toxicity
- Modulating TNFα activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia
- The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia